ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
4,967.23
-0.88%
US Tech 100
16,556.80
-2.24%
Dow Jones
37,986.40
0.56%
Brent Oil
86.625
0.00%
Bitcoin
63,614.75
-0.33%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ

  6. Dare Bioscience Inc (DARE) Quote

Dare Bioscience Inc

Dare Bioscience Inc (DARE)

NASDAQ
0.28
-0.0151
(-5.12%)
Closed April 19 4:00PM
Delayed by 15 minutes
0.2801
0.0001
(0.04%)
After Hours: 7:21PM
Delayed by 15 minutes

Unlock more advanced trading tools

Join ADVFN today

Key stats and details

Current Price
0.2801
Bid
0.2801
Ask
0.2899
Volume
555,803
0.28 Day's Range 0.31
0.27 52 Week Range 1.10
Market Cap
27.597M
Previous Close
0.2951
Open
0.2871
Last Trade
1117
@
0.2801
(formt)
Last Trade Time
Financial Volume
$ 159,484
VWAP
0.286944
Average Volume (3m)
452,252
Shares Outstanding
98,562,344
Dividend Yield
-
PE Ratio
-0.92
Earnings Per Share (EPS)
-0.31
Revenue
2.81M
Net Profit
-30.16M

About Dare Bioscience Inc

Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve... Dare Bioscience Inc is a biopharmaceutical company committed to advancing innovative products for women's health. The company identifies, develops and brings to market a diverse portfolio of differentiated therapies that prioritize women's health and well-being, expand treatment options, and improve outcomes, primarily in the areas of contraception, fertility, and vaginal and sexual health. The company's first product, XACIATO is a single-dose vaginal gel prescription product for the treatment of bacterial vaginosis in females 12 years of age and older. The company's portfolio includes two product candidates in advanced clinical development namely, Ovaprene and Sildenafil Cream. Show more

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
www.darebioscience.com
Headquarters
Wilmington, Delaware, USA
Founded
1970
Dare Bioscience Inc is listed in the Pharmaceutical Preparations sector of the NASDAQ with ticker DARE. The last closing price for Dare Bioscience was $0.30. Over the last year, Dare Bioscience shares have traded in a share price range of $ 0.27 to $ 1.10.

Dare Bioscience currently has 98,562,344 shares outstanding. The market capitalization of Dare Bioscience is $27.60 million. Dare Bioscience has a price to earnings ratio (PE ratio) of -0.92.

DARE Latest News

More News

Daré Bioscience Announces Publication in Contraception of Positive Efficacy and Safety Findings from a Pre-Pivotal Postcoital Test Study of Ovaprene®: an Investigational Hormone-Free Monthly Intravaginal Contraceptive

Published data shows that Ovaprene was safe and effective in a postcoital test study of 33 women Pivotal Phase 3 contraceptive efficacy clinical study of Ovaprene currently enrolling Ovaprene has...

April 11 2024
GlobeNewswire Inc.

Daré Bioscience Reports Full Year 2023 Financial Results and Provides Company Update

2023 Highlights and Anticipated 2024 Milestones XACIATO™ (clindamycin phosphate) vaginal gel 2% is available by prescription in the United States to treat bacterial vaginosis under license...

March 28 2024
GlobeNewswire Inc.

US Stock Futures Stable in Pre-Market On Path for Consecutive Quarterly Gains, Oil Prices Rise

U.S. index futures are nearly unchanged in pre-market trading this Thursday. The indexes are on track to close the second consecutive quarter with positive outcomes, in addition to marking the...

March 28 2024
IH Market News

Daré Bioscience to Host Full Year 2023 Financial Results and Company Update Conference Call and Webcast on March 28, 2024

SAN DIEGO, March 21, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced that it will host a conference call and live webcast...

March 21 2024
GlobeNewswire Inc.

Daré Bioscience to Present at the International Society for the Study of Women’s Sexual Health (ISSWSH) Annual Meeting

Data to be presented demonstrate increased frequency of sexual events with Sildenafil Cream, 3.6% use in the Phase 2b RESPOND clinical study, as well as improvement in multiple aspects of the...

February 22 2024
GlobeNewswire Inc.

Daré Bioscience Announces Positive End-of-Phase 2 Meeting with FDA on Development of Sildenafil Cream, 3.6% in Female Sexual Arousal Disorder and Provides Company Focus Areas for 2024

SAN DIEGO, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, and its collaborator Strategic Science & Technologies, LLC (SST...

January 31 2024
GlobeNewswire Inc.

Form 3 - Initial statement of beneficial ownership of securities

January 29 2024
Edgar (US Regulatory)

Form 8-K - Current report

January 26 2024
Edgar (US Regulatory)

Daré Bioscience Announces Executive Team and Board of Directors Changes

SAN DIEGO, Jan. 26, 2024 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ: DARE), a leader in women’s health innovation, today announced changes in company management which includes the...

January 26 2024
GlobeNewswire Inc.

Form 8-K - Current report

January 19 2024
Edgar (US Regulatory)
PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.1974-41.34031413610.47750.48850.2811172340.29839039CS
4-0.2049-42.24742268040.4850.55990.284739860.37430303CS
12-0.0599-17.61764705880.340.58990.284522520.42877138CS
26-0.2089-42.71983640080.4890.58990.275062190.37318051CS
52-0.7499-72.80582524271.031.10.273772060.50966187CS
156-1.1199-79.99285714291.42.510.2718248971.6371921CS
260-0.7399-72.53921568631.023.850.2714834161.65792108CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TWGTop Wealth Group Holding Ltd
$ 3.73
(101.62%)
36.52M
CSLRComplete Solaria Inc
$ 0.465319
(75.59%)
16.64M
SHOTWSafety Shot Inc
$ 0.48
(60.00%)
6.71k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
MNDRMobile health Network Solutions
$ 27.2386
(33.72%)
10.35M
YYAIConnexa Sports Technologies Inc
$ 0.8943
(-57.21%)
13.4M
SBFMSunshine Biopharma Inc
$ 1.77
(-46.69%)
11.9M
GTIGraphjet Technology
$ 6.43
(-33.09%)
95.33k
ISPCiSpecimen Inc
$ 0.2883
(-31.52%)
2.86M
BGLCBioNexus Gene Lab Corporation
$ 0.5998
(-29.32%)
735.88k
EGOXNext e GO NV
$ 0.0515
(43.06%)
333.3M
SQQQProShares UltraPro Short QQQ
$ 12.84
(6.38%)
219.91M
AGBAAGBA Group Holding Ltd
$ 1.255
(21.84%)
128.79M
TQQQProShares UltraPro QQQ
$ 49.48
(-6.20%)
125.4M
SINTSiNtx Technologies Inc
$ 0.0414
(3.50%)
109.94M

DARE Discussion

View Posts
willlbone willlbone 2 days ago
Vote on R/S.
👍️0
glenn1919 glenn1919 2 months ago
DARE.................................................https://stockcharts.com/h-sc/ui?s=DARE&p=W&b=5&g=0&id=p86431144783
👍️0
starkd748 starkd748 4 months ago
It's dead lol
👍️0
Monksdream Monksdream 4 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 7 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 7 months ago
DARE new 52 week low
👍️0
Monksdream Monksdream 9 months ago
DARE newb52 week low
👍️0
harry crumb harry crumb 1 year ago
Might be a runner in due time
👍️0
nonsequetor nonsequetor 1 year ago
The DARE train has not even left the station... gathering up steam...
👍️0
harry crumb harry crumb 1 year ago
1.00 average, 100k
👍️0
nonsequetor nonsequetor 1 year ago
I hope everyone loaded up Monday...
👍️0
nonsequetor nonsequetor 1 year ago
Monday, Jan 23, is the day...
👍️0
harry crumb harry crumb 1 year ago
Yep agree
👍️0
nonsequetor nonsequetor 1 year ago
If Ovaprene is approved by the FDA, it could be the first monthly non-hormonal contraceptive product for women and a first-in-category option for women seeking a hormone-free, self-administered and monthly birth control method.

https://www.biospace.com/article/releases/dare-bioscience-announces-ide-approval-for-a-single-arm-open-label-pivotal-contraceptive-efficacy-study-of-ovaprene-an-investigational-hormone-free-monthly-intravaginal-contraceptive/
👍️0
nonsequetor nonsequetor 1 year ago
DARE starts revenue soon with its first approved drug, Xaciato and its licensing partner OGN. Q1 or Q2. Milestone payments and double digit royalties.

Additionally, they have up to three products entering Ph3 trials this year: Ovaprene, Sildenafil and HRT-1. Ovaprene for sure is entering Ph3 this summer with NIH and licensing partner $BAYRY.

By 2024, they could have FDA-approved products and $4-$5B market share and exclusivity.
👍️0
nonsequetor nonsequetor 1 year ago
DARE Since Post:
$0.3266
(38.27%)
Then:$0.8534
Now:$1.18

Nice chunk of change so far...
👍️0
harry crumb harry crumb 1 year ago
Mayb, mayb not
👍️0
nonsequetor nonsequetor 1 year ago
Since my call
Jan 03, 2023 9:29 AM

$DARE It has begun...

DARE Since Post:
$0.2566
(30.07%)
Then:$0.8534
Now:$1.11

UM...AH... looks like a winner already...
and it has not even started!

BUT...

I really don't care what negativity others post. I have done my DD, bought low, and will ride the wave to prosperity.

DARE is the real thing, with one of a kind, first in class products, that will turn many heads and make some (who do their own DD) wealthy.

Good fortune to all (except shorts, who bet wrong on this leg up).
👍️0
harry crumb harry crumb 1 year ago
Could be but highly unlikely this becomes a winner
👍️0
nonsequetor nonsequetor 1 year ago
Just a little bit of DD will prove you wrong.
👍️0
harry crumb harry crumb 1 year ago
Dont count on it, this team is not an has not proven anything yet. Could use new management for a change, the stock does note promote a very good company
👍️0
nonsequetor nonsequetor 1 year ago
Hop aboard, this is just the beginning!
👍️0
nonsequetor nonsequetor 1 year ago
DARE up over 30% already this year.
👍️0
nonsequetor nonsequetor 1 year ago
Up 20% in 2 days
👍️0
nonsequetor nonsequetor 1 year ago
UP 10% since yesterday morning.
👍️0
harry crumb harry crumb 1 year ago
This pos needs to be shutdown, what a scam
👍️0
harry crumb harry crumb 1 year ago
Some more news on dare
👍️0
nonsequetor nonsequetor 1 year ago
Daré Bioscience Announces Subject Screening for Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder Complete

https://finance.yahoo.com/news/dar-bioscience-announces-subject-screening-120000980.html
👍️0
harry crumb harry crumb 2 years ago
Some news an this turd is stagnant, very boring company here
👍️0
harry crumb harry crumb 2 years ago
Looks like this pos is going to its 3 yr low of .75 area. What junk!
👍️0
nonsequetor nonsequetor 2 years ago
Q4 will be interesting
👍️0
nonsequetor nonsequetor 2 years ago
WOW!! Nice EOD catapult!!
👍️0
nonsequetor nonsequetor 2 years ago
Another week... another wait...

ZZZZZZZZZZZZZZZZZZZZZZ
👍️0
MattSav MattSav 2 years ago
Good looking week... Hope everyone is enjoying this move upwards... I know we are waiting on 4th quarter for real numbers but wondering if the sentiment here is good enough to through another 10k on shares lol
👍️0
nonsequetor nonsequetor 2 years ago
YES!
👍️0
MattSav MattSav 2 years ago
So should we be excited that they are doing Financials on a Tuesday?
👍️0
MattSav MattSav 2 years ago
So is the corporate presentation today or what I can't open the damn thing
👍️0
nonsequetor nonsequetor 2 years ago
https://www.sec.gov/Archives/edgar/data/0001401914/000149315222019342/ex3-1.htm
👍️0
MattSav MattSav 2 years ago
Anyone find out how the vote went?
👍️0
kruy kruy 2 years ago
You do realize that all the upfront payments and tiered royalties have to be split with the labs that actually invented and produce these products. DARE is only the middleman. These details are all spelled out in the last SEC annual filing.
The best thing that could happen for us shareholders is that some big company that needs a pipeline will buy out this company and its entire complicated business model. Give me $5 a share and I'm happy. Reality wise, I think we could only get $3-$4 because they would need to come to agreements with all the labs that actually engineered all of the products. Either way, I'd be happy with any buyout because the business model as is could take a long time for DARE to break even or show a profit after splitting royalties with all parties involved.
👍️0
nonsequetor nonsequetor 2 years ago
$$$$ Coming in from the Gates!
https://ih.advfn.com/stock-market/NASDAQ/dare-bioscience-DARE/stock-news/88547783/current-report-filing-8-k
👍️0
nonsequetor nonsequetor 2 years ago
This DARE stock will drive a sane man crazy!
👍️0
harry crumb harry crumb 2 years ago
Employee stock incentive plan goes into effect with dare Bod approval. Always good news to have a employee purchase plan for company stock
👍️0
MattSav MattSav 2 years ago
So im new to this stock... What are the opinions of the stock not getting its approval to increase shares?
👍️0
nonsequetor nonsequetor 2 years ago
Just a few more days...
👍️0
nonsequetor nonsequetor 2 years ago
CLINICAL TRIALS RESULTS JUST POSTED
https://www.clinicaltrials.gov/ct2/show/results/NCT03598088?view=results
👍️0
nonsequetor nonsequetor 2 years ago
👍️0
nonsequetor nonsequetor 2 years ago
Main catalyst coming soon: FDA approval of NDE for Ovaprene, non hormonal birth control product. The company already in partnership with Bayer and NIH on this.
$1B
market. NDE approval will trigger the start of a pivotal Ph3 trial this year. Hopefully, their second FDA-approved product by next year. The trial will only cost them $5, and they get a bonus check from Bayer
$20M
on start.

Other pipeline catalysts soon:
1)Xaciato marketing/sales/revenue by Q4 or earlier.
2) VVA-1 Ph2 data: Q3
3) Sildenafil Ph2 data: Q3
👍️0
nonsequetor nonsequetor 2 years ago
From Someone Very Smart
Path to 4.5B MC.

+Initial 10m payment from Organon for Xaciato commencements.
+Sales growth from XACIATO creating a close to breakeven or better cash flow within 2 years. Share price is a reflection of expected future value. Strong sales = big upside potential.
+ Ovaprene IDE acceptance. Bayer thinks that Ovaprene could be it's next billion dollar BC option.
+ $20m Ovaprene payment from Bayer. Would show confidence, solidify balance sheet and give investors more confidence.
+Eventual Ovaprene Approval. $300m+ in incentives + double digit royalties.
+ Sildenafil. Highly likely to be a billion+ annual sales drug with no competition if approved. It alone could boost us to a multi-billion dollar market cap.
+ LARC
+ Deeper pipeline

3 - 5 year horizon. Pretty straightforward path to multi-billion territory."

Long shots - Sale of any of the top 4 candidates. BO of company outright. $6-10 overnight.
👍️0
nonsequetor nonsequetor 2 years ago
Steady and sure... up DARE goes...
👍️0

Your Recent History

NASDAQ
DARE
Dare Bioscience
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved